Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC

NCT04331626 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

DRUG: Gemcitabine Injectable Product

Sponsor

Henan Cancer Hospital